L-瓜氨酸L-苹果酸(1:1) | 41989-03-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-瓜氨酸L-苹果酸(1:1)
• 中文别名: L-精氨酸苹果酸；L-精氨酸苹果酸1:1；精氨酸苹果酸盐
• 英文名称: L-Arginine malate
• 英文别名: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-hydroxybutanedioic acid
• CAS: 41989-03-1；16856-16-9
• 化学式: C10H20N4O7
• 分子量: 308.29
• InChiKey: RUFJTBOKWJYXPM-WCCKRBBISA-N

物化性质

• 熔点：
  227-228℃ (decomposition)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.64
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  223
• 氢给体数：
  7
• 氢受体数：
  9

安全信息

• 海关编码：
  2925290090

反应信息

• 作为试剂：
  描述：

  L-精氨酸 、 L-苹果酸 在 甲醇 、 L-瓜氨酸L-苹果酸(1:1) 作用下， 反应 48.0h， 以to give neutral L-arginine L-malate anhydrate (8.6 g, yield: 71.3%) as colorless granular or prismatic crystal的产率得到L-精氨酸L-苹果酸
  参考文献：
  名称：

  Crystalline salt of basic L-amino acid with L-malic acid and process for

  摘要：

  一种新型晶体盐，由一种碱性L-氨基酸和L-苹果酸组成，特别是由2摩尔的L-赖氨酸、L-鸟氨酸或L-精氨酸和1摩尔的L-苹果酸组成的中性晶体盐，没有苦味，可以口服作为营养补充剂或药物，且不含氯离子，因此可用于制备无氯离子副作用的输液溶液。

  公开号：

  US04420432A1

文献信息

• Apo2 ligand/TRAIL formulations
  申请人：Genentech, Inc.

  公开号：EP2322165A1

  公开（公告）日：2011-05-18

  The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.

  本发明包括载脂蛋白 2L/TRAIL制剂和使用这种制剂的方法。本发明提供了稳定且具有更好的 Apo2L/TRAIL 三聚体形成的 Apo2L/TRAIL 冻干和晶体制剂。还提供了制造 Apo-2L/TRAIL 制剂的方法，以及含有此类制剂的设备和试剂盒。
• ARGININE AND ITS USE AS A T CELL MODULATOR
  申请人：Institute for Research in Biomedicine

  公开号：EP3308778A1

  公开（公告）日：2018-04-18

  The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T cell responses.

  本发明为基于 T 细胞的免疫疗法提供了新的用途和方法。具体地说，本发明涉及新型配体、靶标以及编码所述靶标的核酸和载体，它们可用于调节 T 细胞反应。
• Chemical mechanical polishing method for tungsten
  申请人：Rohm and Haas Electronic Materials CMP Holdings, Inc.

  公开号：US10600655B2

  公开（公告）日：2020-03-24

  A process for chemical mechanical polishing a substrate containing tungsten to at least reduce dishing of tungsten features of 100 μm or less. The process includes providing a substrate containing tungsten features of 100 μm or less; providing a polishing composition, containing, as initial components: water; an oxidizing agent; arginine or salts thereof; a dicarboxylic acid, a source of iron ions; a colloidal silica abrasive; and, optionally, a pH adjusting agent; and, optionally, a surfactant; and, optionally, a biocide; providing a chemical mechanical polishing pad, having a polishing surface; creating dynamic contact at an interface between the polishing pad and the substrate; and dispensing the polishing composition onto the polishing surface at or near the interface between the polishing pad and the substrate; wherein some of the tungsten is polished away from the substrate and yet at least reducing dishing of the tungsten features of 100 μm or less.

  一种对含钨基底进行化学机械抛光以至少减少 100 μm 或以下钨特征的分层的工艺。该工艺包括提供含有 100 μm 或更小钨特征的基底；提供抛光组合物，作为初始成分，该组合物含有水；氧化剂；精氨酸或其盐；二羧酸；铁离子源；胶体二氧化硅磨料；可选的 pH 值调节剂；可选的表面活性剂；可选的杀菌剂；提供具有抛光表面的化学机械抛光垫；在抛光垫和基底之间的界面处产生动态接触；以及在抛光垫和基底之间的界面处或其附近将抛光组合物分配到抛光表面上；其中部分钨被抛光离开基底，但至少减少了 100 μm 或更小的钨特征的分层。
• Arginine and its use as a T cell modulator
  申请人：INSTITUTE FOR RESEARCH IN BIOMEDICINE

  公开号：US11167015B2

  公开（公告）日：2021-11-09

  The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T cell responses.

  本发明为基于 T 细胞的免疫疗法提供了新的用途和方法。具体地说，本发明涉及新型配体、靶标以及编码所述靶标的核酸和载体，它们可用于调节 T 细胞反应。
• Apo-2 ligand/trail formulations
  申请人：Flores Heather

  公开号：US20050020498A1

  公开（公告）日：2005-01-27

  The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.

  本发明包括载脂蛋白 2L/TRAIL制剂和使用这种制剂的方法。本发明提供了稳定且具有更好的 Apo2L/TRAIL 三聚体形成的 Apo2L/TRAIL 冻干和晶体制剂。还提供了制造 Apo-2L/TRAIL 制剂的方法，以及含有此类制剂的设备和试剂盒。